Study limitation: The breast cancer protective association in BRCA2 carriers (HR 0.80) lacks a consistent duration-response pattern across subgroups; the authors themselves caution against overinterpretation | ReachRx
Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant
Study limitation reported by the research below: “The breast cancer protective association in BRCA2 carriers (HR 0.80) lacks a consistent duration-response pattern across subgroups; the authors themselves caution against overinterpretation.”
